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Abstract
Background: Self-harm is common in the community with a lifetime prevalence of 13 %. It is associated with an
elevated risk of overall mortality and suicide. People who harm themselves are high users of public services. Estimates of
the 1-year risk of repetition vary between 5 and 15 % per year. Currently, limited evidence exists on the effectiveness of
clinical interventions for young people who engage in self-harm. Recent reviews have failed to demonstrate any effect
on reducing repetition of self-harm among adolescents receiving a range of treatment approaches. Family factors are
particularly important risk factors associated with fatal and non-fatal self-harm among children and adolescents. Family
therapy focuses on the relationships, roles and communication patterns between family members, but there have been
relatively few studies of specifically family-focused interventions with this population. The Self-Harm Intervention: Family
Therapy (SHIFT) Trial was funded by the National Institute for Health Research (NIHR) Health Technology Assessment
programme (grant no. 07/33/01) following a commissioned call for this research.
Methods/Design: SHIFT is a pragmatic, phase III, multicentre, individually randomised, controlled trial comparing Family
Therapy (FT) with treatment as usual (TAU) for adolescents aged 11 to 17 who have engaged in at least two episodes of
self-harm. Both therapeutic interventions were delivered within the National Health Service (NHS) Child and Adolescent
Mental Health Services (CAMHS) in England. Participants and therapists were, of necessity, aware of treatment allocation,
but the researchers were blind to the allocations to allow unbiased collection of follow-up data. Primary outcome data
(repetition of self-harm leading to hospital attendance 18 months post-randomisation) were collected from the Health
and Social Care Information Centre (HSCIC), augmented by directed searches of medical records at Acute Trusts.
Secondary outcome data (including suicidal intent, depression, hopelessness and health economics) were collected at
12 and 18 months post-randomisation via researcher-participant interviews and by post at 3 and 6 months.
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Discussion: SHIFT will provide a well-powered evaluation of the clinical and cost effectiveness of Family Therapy for
young people who have self-harmed on more than one occasion. The study will be reported in 2016, and the results
will inform clinical practice thereafter.
Trial registration: ISRCTN59793150. 26 January 2009.
Keywords: Self-harm, suicide, young people, child and adolescent mental health, family therapy, randomised
controlled trial
Background
The SHIFT Trial protocol was developed in response to
a commissioned call for research. In accordance with the
commissioning brief and in line with current UK clinical
practice, self-harm is defined as any form of non-fatal
self-poisoning or self-injury (such as cutting, taking an
overdose, hanging, self-strangulation, jumping from a
height, and running into traffic), regardless of motivation
or the degree of intention to die. This definition includes
what in the United States would be described as non-
suicidal self-injury.
Self-harm is common in the community; a systematic
review suggested a lifetime prevalence of self-harm of
13 % [1], whilst a recent meta-analysis reported an
adjusted lifetime prevalence of non-suicidal self-injury of
17 % [2]. Self-harm is associated with an elevated risk of
overall mortality [3–6] and suicide. In one follow-up study
[7] of 15- to 24-year olds, who had presented to hospital
following an episode of self-harm, the overall number of
deaths from all causes was 3 % of cases, four times higher
than expected. This was mainly due to an excess number
of suicides (2 %), which were 10 times more frequent than
expected. A recent multicentre study of those under 18
presenting following self-harm found that while mortality
was relatively low at 0.9 % at a median follow-up period of
6 years, nearly half of these deaths were due to suicide [8].
Due to the young ages at which these deaths occur, the life
years lost to the community due to suicide and the impact
on family members are considerable.
Around 20–30,000 adolescents present to hospital each
year having harmed themselves [9] although this repre-
sents only one in eight episodes of self-harm because the
majority of young people who self-harm do not present to
hospital [10]. Rates of self-harm amongst young people in
the UK are not declining [11], and the epidemiology of
self-harm appears to be shifting with dangerous methods
such as hanging increasing in females [12], with higher
rates among South Asian young women [13]. People who
harm themselves are high users of public services [14],
and increasing rates of self-harm will lead to an even
greater demand for services.
In studies based on presentations to general hospitals in
the UK, the majority of adolescents have harmed them-
selves by taking an overdose; self-poisoning with
analgesics is particularly common [11, 15] and dangerous
due to the risk of death from liver failure. At the commu-
nity level, the most common methods of self-harm are
cutting and overdose [10]. Young people have a poor un-
derstanding of the potential lethality of methods of self-
harm, so interventions to prevent further episodes of self-
harm is one approach to reducing both the morbidity and
mortality associated with these acts.
Estimates of risk of 1-year repetition vary between 5
and 15 % per year [16], with 18 % in a recent UK multi-
centre monitoring study of over 5000 adolescents [11]
and as much as 27 % in an average of 5 years of follow-
up of around 4000 adolescents [8]. In addition, actual
rates may be much higher if repetition that does not
come to clinical attention is considered [9]. The risk of
repetition is highest in the first year, but may remain
high for many years after an episode [4, 17].
Currently, there is limited evidence about the effective-
ness of clinical interventions for young people who engage
in self-harm, although there has been much work in the
area since the earliest systematic review [18]. Recent re-
views have failed to demonstrate any effect on reducing
repetition of self-harm among adolescents receiving a
range of treatment approaches including therapeutic
assessments and compliance enhancement in hospitals,
youth-nominated support teams, tokens for hospital
admission and home and family-focused interventions
[19, 20]. The early promise of developmental group
psychotherapy has not been replicated in larger studies
[20]. Brent et al. [21] focused on aspects of trials that
showed promise and concluded that interventions that
activated family support, addressed motivations for
change, were quickly mobilised (to reflect the elevated
risk of repetition immediately post-episode) and pro-
moted a positive affect are most likely to be able to
demonstrate effectiveness. The heterogeneity of treat-
ment as usual (TAU) and the lack of its characterisation
of TAU [21], in addition to the many underpowered
studies, have held back advances in this field.
Family factors are particularly important risk factors as-
sociated with fatal and non-fatal self-harm among children
and adolescents [20, 22–25]. Difficulties in parent–child
relationships, including those related to early attachment
problems, and perceived low levels of parental caring and
Wright-Hughes et al. Trials  (2015) 16:501 Page 2 of 12
communication are related to increased risk of suicide and
self-harm among children and adolescents [26]. A family
history of self-harm is associated in adolescents with in-
creased risk for suicide deaths [27–29] and for non-fatal
self-harm [10, 30]. Parental mental illness and substance
abuse are significant risk factors [16]. A strong association
exists between self-harm and both childhood sexual abuse
and physical abuse [31]. Young people who self-harm ex-
perience higher rates of exposure to recent stressful life
events such as rejection, conflict or loss following the
break-up of a relationship, conflicts and disciplinary or
legal crises [15].
Systemic family therapy focuses on mobilising family
resources and on the relationships, roles and communica-
tion patterns between family members. Surprisingly, there
is only a small amount of literature on the use of family
therapy with young people who self-harm [32–34], with
most studies not powered to detect reductions in repeat
self-harm. The SHIFT study seeks to evaluate the potential
clinical and cost effectiveness of a family therapeutic inter-
vention following adolescent self-harm.
Methods/Design
Design
SHIFT is a pragmatic, phase III, multicentre, individually
randomised, controlled trial comparing Family Therapy
(FT) with treatment as usual (TAU) for adolescents aged
11 to 17 who have engaged in at least two episodes of
self-harm. An individually randomised design (Fig. 1) was
chosen over a cluster randomised design as the risk of
contamination between the two treatment arms was min-
imal: participants attended appointments at varying times
and so could not cross compare, and family therapists
were specifically instructed not to treat any participants in
the TAU arm of the trial wherever possible.
Trial objectives and outcomes
The primary objective of the SHIFT trial is to assess the ef-
fectiveness of FT compared to TAU as measured by rates
of repetition of self-harm leading to hospital attendance
18 months after randomisation. This primary outcome was
selected because it is an objective measure of self-harm.
This outcome can be quantified using routine hospital
Fig. 1 Trial design flow diagram
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records data rather than relying on participant self-report
and can be obtained even if contact has been lost with par-
ticipants, thereby maximising the accuracy and complete-
ness of the data collection.
Secondary objectives are to assess the following:
1. The effectiveness of FT compared to TAU, measured
by repetition rates of self-harm leading to hospital
attendance at 12 months after randomisation.
2. The cost per self-harm event avoided due to FT,
measured using a structured health economics
questionnaire designed by the trial health economist
to be specific to this population.
3. The characteristics of further episodes of self-harm
(all episodes, not just those resulting in hospital at-
tendance). This includes the number of subsequent
self-harm events, time to next event, severity of event
(fatal, near fatal or not) and dangerousness of the
method used, as measured by the Suicide Attempt
Self-Injury Interview (SASII) [35].
4. Suicidal ideation in each trial arm, measured by the
Beck Scale for Suicide Ideation [36].
5. Quality of life in each arm, measured by the Paediatric
quality of Life Enjoyment and Satisfaction measure
(PQ-LES) [37] and parental completion of the General
Health Questionnaire-12 (GHQ-12) [38].
6. Depression in each arm, measured by the Children’s
Depression Rating Scale – Revised (CDRS-R) [39].
7. Overall mental health and emotional and
behavioural difficulties in each arm via young person
and parental completion of the Strengths and
Difficulties Questionnaire (SDQ) [40].
8. Hopelessness in each arm, via completion of the
Hopelessness Scale for Children [41].
9. Family functioning in each arm, measured by the
McMaster Family Assessment Device [42] and the
Family Questionnaire [43].
10.Mediator and moderator variables that influence
engagement with and benefit from treatment (for
example, number of sessions, medication use,
referrals, mediators).
11.Therapeutic alliance to family therapy, via family
therapist, young person and parental completion of
the System for Observing Family Therapy Alliances
(SOFTA) [44].
12. Therapist adherence to the family therapy manual.
A trial-specific approach has been developed for
independent review of a representative sample of
recorded FT sessions.
Recruitment setting and participants
Young people and their primary caregivers were identified
from 40 National Health Service (NHS) Child and Adoles-
cent Mental Health Services (CAMHS) across three ‘hubs’
in England - Greater Manchester, London and Yorkshire.
Following consultation with service users and clinicians,
we elected not to screen young people at first presentation
in the emergency department or primary care because in
this time of crisis, immediately following the self-harm
event, young people and their families would not be in a
position to readily give fully informed consent. Young
people were therefore screened for trial suitability at
their first presentation to CAMHS following self-harm.
They would thus have already been assessed by the
emergency department staff, on-call CAMHS staff in
hospital or by primary/community health staff before
referral to CAMHS, where the screening took place. To
be included in the trial, participants were required to
meet the eligibility criteria described next.
Inclusion criteria
Inclusion criteria included the following:
1. Aged 11–17 years.
2. Self-harmed prior to assessment by the CAMHS team
(self-harm being the key feature of presentation).
3. Engaged in at least one previous episode of self-
harm (recorded by CAMHS or via self-report) prior
to the index presentation.
4. Where the presenting episode was due to alcohol or
recreational drugs, the young person had explicitly
stated that he / she was intending self-harm by use
of these substances.
5. The clinical intention was to offer CAMHS follow-
up for self-harm.
6. Lived with primary care-giver.
7. Both young person and primary care-giver gave writ-
ten informed consent, as appropriate.
Exclusion criteria
Exclusion criteria include the following:
1. At serious risk of suicide (clinical judgement);
2. An ongoing child protection investigation within the
family, which would have made treatment difficult
to deliver;
3. Would not have ordinarily been treated in generic
CAMHS but rather by a specific service (for
example, psychiatric inpatient care for severe major
depressive disorder);
4. Pregnant at time of trial entry;
5. Actively being treated in CAMHS (as the possibility
of randomisation might disrupt ongoing therapy);
6. In a children’s home or short-term foster placement;
7. Moderate to severe learning disability or lacked
capacity to comply with trial requirements;
8. Involved in another research project - at the time of
trial entry or within the last six months;
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9. Sibling had been randomised to the SHIFT trial, or
was receiving family therapy within CAMHS; or
10.The young person and one main care-giver had in-
sufficient proficiency in English to contribute to the
data collection.
All young people presenting to CAMHS following self-
harm were screened. Data were recorded anonymously for
those not meeting the above criteria in order to monitor
trial uptake and representativeness of the trial population.
Where a young person met the criteria, the assessing
CAMHS clinician discussed trial participation at the as-
sessment appointment, passed on the participant informa-
tion sheets and requested consent for subsequent contact
by a researcher. Those providing such consent were con-
tacted by the researcher, who arranged to visit the family
at home, obtained consent for participation in the trial
and administered the baseline assessment.
Recruitment, randomisation and blinding
Where the appropriate consent was obtained and base-
line assessment completed, the researchers randomised
participants sequentially via an automated system at the
Clinical Trials Research Unit (CTRU) at the University
of Leeds. Participants were randomly allocated on a 1:1
basis to receive FT or TAU, using a computer-generated
minimisation programme incorporating a random elem-
ent to ensure the treatment arms were well balanced for
the following: centre (CAMHS team), gender, age (11 to 14
or 15 to 17), living arrangements (with parents or guard-
ians/foster care), number of previous self-harm episodes
(including index event) (2 or ≥ 3), and type of index epi-
sode (self-poisoning, self-injury, or combination). Where
therapists were not aligned to a specific service but covered
a number of services, additional randomisation of the lead
therapist took place within the FT team in order to minim-
ise case-selection bias.
Participants and therapists were, of necessity, aware of
treatment allocation, but researchers were blind to the
allocation to allow unbiased collection of follow-up data.
CTRU was responsible for informing CAMHS clinicians
and family therapists of randomisation outcome, to main-
tain researcher blinding.
Data collection
Required data, assessment tools, collection time points
and processes are summarised in Table 1.
Baseline
At the baseline assessment, the researcher administered
questionnaires to the young person, and self-reported
questionnaires were also completed by the young person
and the consenting primary caregiver.
Follow-up
The primary outcome measure was obtained from Acci-
dent and Emergency Departments (A&E) and in-patient
Hospital Episode Statistic (HES) data downloads from the
NHS Health and Social Care Information Centre
(HSCIC), which holds hospital attendance and admission
data for hospitals across England. This method of primary
outcome data collection was augmented by directed
hospital record searches, undertaken by researchers
at frequent intervals throughout the trial. Researchers
searched Acute Trust records for episode details that
were unclear from the central HES data, or for any
hospital attendances for those participants who had
not consented to the trial team providing their de-
tails to the HSCIC. Given that HES data sets are
England-wide, this maximised collection of hospital
attendance data, allowing for participants moving out
of catchment area (within England). Collection of
these routine data also minimised bias by eliminating
the possibility of preferential researcher data collec-
tion at certain Acute Trusts.
Postal questionnaires were administered by CTRU at 3
and 6 months post-randomisation. If questionnaires were
not returned, postal reminders were sent 2 weeks after the
initial mailing and then again a further 2 weeks later.
Secondary outcome were obtained via face-to-face
researcher interviews at 12 and 18 months following
randomisation.
Data relating to treatment were provided by the treating
CAMHS clinicians or Family Therapists, Clinical Studies
Officers (CSOs) employed by the Research Networks in
each locality and by the researchers, when blinding was no
longer required (that is, after participant-reported follow-
up data had been collected). The data included session at-
tendance (FT and TAU), therapeutic approach (for TAU),
referrals within and outside CAMHS, requirements for
psychotropic medications, and liaison with other agencies.
In addition, treating clinicians and participants completed
the System for Observing Family Therapy Alliances scale
(SOFTA) [44] at the end of the third treatment session.
Supervision sessions for Family Therapists, and routinely
provided clinical supervision for CAMHS clinicians were
also recorded.
Intervention
Both therapeutic interventions were delivered within
CAMHS, and all participants were treated within their
local service. Family therapists were formally linked
with specific CAMHS teams to ensure lines of clinical
responsibility were clear, and all clinicians in both arms
of the trial had access to local child and adolescent psy-
chiatrists if medication or hospitalisation needed to be
considered.
Wright-Hughes et al. Trials  (2015) 16:501 Page 5 of 12
Family therapy
The Family Therapy intervention was based on a modified
version of the Leeds Family Therapy & Research Centre
Systemic Family Therapy Manual (LFTRC Manual), the
development and validation of which was funded by the
Medical Research Council (MRC) to support trials of FT
[45]. This manual was updated by the Family Therapy ex-
pert members from the Trial Management Group to
ensure it was appropriate for work with families following
self-harm. Qualified Family Therapists (those eligible for
registration with the UK Council for Psychotherapy -
UKCP) were appointed specifically to work on the trial.
Family therapists worked in teams of 3 or 4 and provided
trial FT as a team for a cluster of CAMH services. They
received initial training, undertook pilot work and re-
ceived monthly supervision from the SHIFT Family
Table 1 Summary of assessments
Assessment (including who is involved) Timeline (months post-randomisation)
Baseline 3 6 12 18
Eligibility and consent
- Eligibility (assessed by clinician) X
- Consent (YP, P, Ra) X
Background and demographics (YP, P, R - interview and case notes)
- Personal details X
- Outline ‘index’ event details X
- Current co-morbid physical/mental health X
- Current psychotropic medications X
- History of abuse X
Follow-up data (collected from case notes)
- Therapy details (provided by therapist) X X
- Therapist supervision details (provided by therapist/supervisor) X X
- Details of further self-harm episodes since consent (R) X X
- Psychotropic medication details (R) X X
- Referrals to other MH services (R) X X
- Re-referral to CAMHS (R) X X
- Admissions to hospital relating to mental health (R) X X
- All-cause mortality (CTRU to collect via MRIS flagging) X
- Serious adverse event reporting and hospital attendance (R and HSCIC) Ongoing collection
Questionnaires (completed at researcher visit unless otherwise stated)
- Family Questionnaire (P self-report, CTRU postal admin at 3 and 6 months) X X X
- System for Observing Family Therapy Alliances - SOFTA (completed by the family
therapist and participants at Family Therapy session 3)
X
- Suicide Attempt Self-Injury Interview - SASII (Interview with YP) X X X
- Beck Scale for Suicide Ideation (YP self-report) X X X
- Hopelessness Scale for Children (YP self-report) X X X
- McMaster Family Assessment Device – FAD (YP and P self-report) X X X
- General Health Questionnaire 12 – GHQ (P self-report) X X X
- Strengths and Difficulties Questionnaire - SDQ (YP and P self-report) X X X
- Children’s Depression Rating Scale – CDRS (Interview with YP) X X X
- Paediatric Quality of Life Enjoyment and Satisfaction – PQ-LES (YP self-report) X X X
- Inventory of Callous Unemotional Traits - ICU (YP self-report) X
- EQ-5D (YP self-report, CTRU postal admin at 6 months) X X X X
- Health Utilities Index 3 – HUI3 (P self-report, CTRU postal admin at 6 months) X X X X
- Health Economics questionnaire (YP and P self-report, CTRU postal admin at 3 and 6 months) X X X X X
aYP, young person; P, parent/care-giver; R, researcher; HSCIC, NHS Health and Social Care Information Centre
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Therapy leads in each locality. Annual meetings of the
trial therapists were organised to ensure ongoing
consistency of the treatment approach across all trial sites.
Plans were made for the young people and their families
to attend FT sessions of approximately 1¼ hours duration
each, delivered over 6 months at approximately monthly
intervals but with more frequent initial appointments.
This equated to approximately 8 sessions, but there was
the expectation that some participants would receive
fewer sessions due to drop-out or mutually agreed-upon
termination of treatment. Equally, it was anticipated
that some might receive more sessions (within the pre-
defined 6-month period, or extending beyond 6 months)
where this was deemed clinically appropriate.
Wherever possible, and where consent was provided,
sessions were video recorded as this is part of good family
therapy practice and facilitates supervision. In addition,
this procedure facilitated central review of a selection of
sessions to monitor adherence to the manual and allow
reporting of this.
Treatment as usual
TAU was the care offered by local CAMHS teams to
adolescents referred following self-harm. This treatment
was anticipated to be diverse and involve individual
and/or family-orientated work, delivered by a range of
practitioners with various theoretical orientations. As
SHIFT is a pragmatic trial involving a number of collab-
orating CAMHS teams, the specification of TAU was
not deemed possible or appropriate, although it was
expected that CAMHS practitioners would be working
in line with best practice as set out in several National
Institute for Health and Care Excellence (NICE) guide-
lines (for example, guidance on self-harm and depres-
sion in childhood [46, 47]). TAU thus involved a wide
range of treatment techniques and modalities (such as
supportive counselling or cognitive behaviour therapy)
that were not delivered to the FT group as part of the
clinical intervention, unless they became indicated dur-
ing or after family therapy.
Contamination
The possibility of cross-arm contamination was consid-
ered during the design stage of the trial, with the follow-
ing points noted and action taken:
1. Different teams of therapists delivered the two
interventions in each CAMH service, and the SHIFT
family therapists were prohibited (wherever possible)
from treating participants in the TAU arm for the
duration of the trial. However, in the few cases
where this was unavoidable, contamination was
recorded and levels will be reported.
2. Due to the nature of appointment scheduling, and
the fact that this was family-specific therapy (that
is, not a group intervention), there was little
opportunity for participants to meet and discuss
treatment, so contamination was very unlikely.
3. Any family-orientated clinical interventions in the
TAU group were likely to be different from the trial
FT intervention, which required adherence to the
LFTRC manual, fully-trained family therapists eligible
for United Kingdom Council for Psychotherapy
(UKCP) registration, therapy delivered in a team
context and regular supervision.
Safety monitoring
Non-serious adverse events were operationally defined
in SHIFT as treatment on an emergency outpatient basis
(A&E attendance) and re-referral to CAMHS, as these
events are expected to occur within the adolescent study
population. Deaths and hospital admissions were defined
as serious adverse events because, although not as com-
mon, they are to be expected in the population being
studied.
An independent Data Monitoring and Ethics Committee
(DMEC) is scheduled to meet at least annually to review
the safety and ethics of the trial during recruitment and
follow-up. The DMEC review the number and frequency
of hospitalisations and deaths overall and as a consequence
of self-harm and could recommend trial suspension or
closure if a significantly increased frequency of such events
in one or both arms is identified.
Research governance
The Trial is managed on a day-to-day basis by the Chief
Investigator and a core team from the Clinical Trials
Research Unit at the University of Leeds. All collaborators,
including trial research staff, form the Trial Management
Group, which meets on a regular basis to review progress.
Independent oversight is provided by the Trial Steering
Committee and Data Monitoring and Ethics Committee.
The trial was reviewed and approved by the NHS Re-
search Ethics Committee (REC) Yorkshire and the Hum-
ber - Leeds West (REC reference 09/H1307/20). SHIFT
also received R&D approval from all participating CAMHS’
host organisations. For the purposes of collecting routine
data from Acute Trusts to inform the primary outcome,
the REC agreed that the study was exempt from Site Spe-
cific Assessment, but Researchers required Letters of Ac-
cess from each Trust to access records. Participants could
withdraw from further researcher contact, receipt of postal
questionnaires or collection of clinical data from CAMHS/
Acute Trusts/HSCIC. Withdrawal requests were respected
throughout the trial and data were only obtained where
valid consent remained in place.
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The following organisations gave research governance
approval for the study:
5 Boroughs Partnership NHS Foundation Trust
Airedale NHS Foundation Trust
Alder Hey Children’s NHS Foundation Trust
Barnet and Chase Farm Hospitals NHS Trust
Barnet, Enfield and Haringey Mental Health NHS Trust
Bolton NHS Foundation Trust
Bradford District Care NHS Foundation Trust
Bradford Teaching Hospitals NHS Foundation Trust
Calderdale & Huddersfield NHS Foundation Trust
Central Manchester University Hospitals NHS
Foundation Trust
Croydon Health Services NHS Trust (formerly Mayday)
Dartford and Gravesham NHS Trust
East London NHS Foundation Trust
Guy’s and St Thomas’ NHS Foundation Trust
Harrogate and District NHS Foundation Trust
Homerton University Hospital NHS Foundation Trust
Hull and East Yorkshire Hospitals NHS Trust
Humber NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Leeds Community Healthcare NHS Trust
Leeds Teaching Hospitals NHS Trust
Leeds and York Partnership NHS Foundation Trust
Lewisham Healthcare NHS Trust
The Mid Yorkshire NHS Trust
North Lincolnshire and Goole Hospitals NHS
Foundation Trust
North Middlesex University Hospital NHS Trust
Oxleas NHS Foundation Trust
Pennine Acute Hospitals NHS Trust
Pennine Care NHS Foundation Trust
Royal Free Hampstead NHS Trust
St George’s Healthcare NHS Trust
St Helens and Knowsley Teaching Hospitals NHS Trust
Salford Royal NHS Foundation Trust
Scarborough and NE Yorkshire Healthcare NHS Trust
South London and Maudsley NHS Foundation Trust
South London Healthcare NHS Trust
South Tees Hospitals NHS Foundation Trust
South West Yorkshire Partnership NHS Foundation
Trust
Stockport NHS Foundation Trust
Tameside Hospital NHS Foundation Trust
The Tavistock and Portman NHS Foundation Trust
Trafford Healthcare NHS Trust
University College London Hospitals NHS Foundation
Trust
University Hospital of South Manchester NHS
Foundation Trust
Wakefield District Primary Care Trust
Warrington and Halton Hospitals NHS Foundation
Trust
Whittington Health NHS
Wrightington, Wigan and Leigh NHS Foundation Trust
York Teaching Hospital NHS Foundation Trust
Statistical considerations
Power calculation/sample size consideration
The power calculation was based on a minimally import-
ant reduction in 18-month repetition rates of self-harm
(leading to hospital attendance) from 29 % in participants
receiving TAU [48] to 18.8 % in participants receiving FT,
that is, a reduction of 35 %. Using a 5 % significance level
log-rank test for equality of survival curves, 374 partici-
pants per arm were required, with 172 total events, to give
90 % power to detect this reduction in 18 month repeti-
tion rates, providing a constant hazard ratio of 1.64. As-
suming at most a 10 % loss to follow-up by 18 months for
the primary outcome, the total sample size required was
416 per arm, 832 in total.
Although SHIFT is an individually randomised trial, in-
herent clustering within the data structure (participants
nested within therapists) is known to have an impact on
power and is related to the level of the intra-cluster correl-
ation coefficient (ICC) and the cluster size. It was expected
that the level of clustering would be low - possibly around
0.01 but no higher than 0.05 (due to use of therapy
manuals, therapist selection, training, supervision and
monitoring). In addition, the number of participants per
therapist was expected to be small. In the TAU arm, it was
estimated that there would be between eight and 15 thera-
pists available in the team at any one centre, so across the
anticipated 15 participating Trusts there would be 120 to
225 therapists available to treat 416 participants. Thus,
each therapist would treat between two and four partici-
pants (maximum control cluster size of 4). In the FT arm,
we estimated that there would be approximately 35 thera-
pists available across all the sites to treat 416 participants;
operating in teams of three or four therapists. Within each
FT team, each therapist would be the lead for a subset of
participants at that site (the other therapists in the team
would act as observers and make only a small face to face
contribution for those participants). Thus, each FT therap-
ist would have direct contact with approximately 12 par-
ticipants (maximum intervention cluster size of 12).
The design effect, describing the extent to which the
sample size must be increased to obtain the same power
as an individually randomised study without clustering,
was therefore assumed likely to be no greater than 1.55
(assuming an ICC of 0.05), effectively reducing the sam-
ple size from 416 per group to 270 per group and the
power from 90 % to around 75 %. If the ICC were as
low as 0.01, then the design effect would be 1.11, redu-
cing the sample size to 374 per group and the power to
around 85 %. We anticipated the ICC would be towards
the lower end of the possible range, and therefore, the
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trial would still be adequately powered with the sample
size planned.
Statistical analysis
A single formal interim analysis was planned on the pri-
mary endpoint, repetition of self-harm leading to hospital
attendance within 18 months of randomisation, when at
least half the required number of events had been reached
(86 events). The DMEC, in light of the interim data and of
any advice or evidence they wished to request, would if
necessary report to the Trial Steering Committee with a
recommendation of trial adaptation or early closure if,
compared with TAU, the effect of FT was significantly in-
ferior (P < 0.005). Final analyses are not planned until all
participants have reached the end of the follow-up period,
when it is expected that at least 172 events will have
occurred.
All analyses, unless otherwise specified, will be con-
ducted on the intention-to-treat population defined as all
participants randomised regardless of non-compliance with
the intervention. An overall two-sided 5 % significance
level will be used for all endpoint comparisons. For the pri-
mary endpoint, this will be adjusted to account for the
planned interim analysis. The O’Brien and Fleming alpha
spending function will be used [49], allowing an alpha level
of 0.047 for the final analysis and 0.005 for the interim
analysis.
Primary endpoint analysis
Cox’s Proportional Hazards Model accounting for the
minimisation factors will be used to test for differences in
18-month repetition rates. Hazard Ratios and correspond-
ing 95 % confidence intervals (CIs) will be presented. If a
participant is lost to follow-up, they will be treated as
censored. Kaplan-Meier curves will be constructed for
each group and compared using a two-sided log-rank test.
Although the significance level has been slightly reduced
to account for an interim analysis, CIs will still be pre-
sented at the 95 % level. The extent of clustering on
participant outcomes due to therapists and the impact on
the precision of the treatment effect estimate will be inves-
tigated using multilevel survival frailty models in a second-
ary analysis. Sensitivity analysis will also be used to assess
the impact of missing details of hospital attendance should
they remain by the time of analysis (that is, where it is un-
clear whether an attendance was due to self-harm or not).
Secondary endpoint analysis
The analysis of 12-month repetition rates will follow that
of the 18-month data detailed in the primary endpoint
analysis. Further episodes of self-harm will be analysed
using a multiple events analysis based on Andersen-Gill
[50] methodology, making use of the timing and cumula-
tive number of first and subsequent events. For other
measures, such as suicidal ideation and quality of life,
mean scores and 95 % CIs (adjusted for baseline) will be
presented for each time point, and repeated measures
models will be used to estimate differences between the
treatment groups. Mediator and moderator variables,
which influence engagement with and benefit from treat-
ment, will be identified by modelling the relationship be-
tween process variables (for example, number of sessions,
medication use, referrals, mediators) and outcomes in a
complier average causal effect (CACE) analysis, and via in-
clusion of potential moderators as an interaction effect in
the primary analysis model. In addition, we will summarise
adherence and alliance to family therapy.
Health economic analysis
The economic evaluation will estimate costs of treatments
and, if appropriate, the incremental cost-effectiveness of FT
compared to TAU in the management of self-harm in ado-
lescents. Two sets of economic evaluation will be under-
taken: a set of within-trial analyses and a decision analytic
model over a longer time horizon.
Within-trial economic evaluation analysis
The within-trial evaluation will compare the outcomes
and cost up to 18 months follow-up using trial data. In
line with the NICE reference case [51], the primary out-
come will be quality-adjusted life years (QALYs). The
combination of answers to the EQ-5D will lead to a
health profile of five digits [52], which will be converted
into utility using standard UK tariff values [53]. These
utilities will represent patients’ overall quality of life and
will be multiplied by the time spent in each state to gen-
erate QALYs. Costs will include any resource usage in-
curred to the NHS and Social Services while providing
FT or TAU - as well as records of hospital attendance,
and of primary, community or social care service attend-
ance, and medications reported in the health economics
questionnaire over the follow-up. Resource usage figures
will be converted into costs using unit cost figures from
the PSSRU Costs of Health and Social Care [54] and the
Department of Health’s Reference Costs [55]. The dis-
count rate will be 3.5 % as per the NICE guidelines [51]
and parameter uncertainty will be addressed through
probabilistic sensitivity analysis. This analysis will use
the non-parametric bootstrap method to generate simu-
lations of the mean costs and effects for each arm of the
trial. The same within-trial analysis will be carried out
using repetition of self-harm as a secondary outcome.
Decision analytic model
The decision analysis model will evaluate the cost-
effectiveness of FT compared to TAU over a longer time
horizon using QALY as the outcome and all health and so-
cial care costs. The model will rely on the results of the
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within-trial analysis and literature searches. Ideally the
time horizon of interest would be a lifetime horizon; how-
ever, this does not have any precedence in the literature. A
cohort of young people will face such a large number of
events over their adult life that building a decision analysis
model that can reflect real life would be difficult and re-
quire would a massive amount of assumption and prob-
abilities to estimate. It will be more realistic to consider
shorter time horizons.
We will initially consider extrapolating the cost-
effectiveness of FT compared to TAU in the management
of self-harm in adolescents up to 5 years after they were
randomised in the trial. If we find appropriate literature
references from which we can make reliable assumptions
and extract appropriate probabilities, we will additionally
consider modelling the cost-effectiveness up to the time
when the adolescent enters adulthood (20 years old). We
will design a Markov model with three health states: stop
self-harm, repeat self-harm and death. Depending on the
findings from the within-trial analysis and the time to re-
peat self-harm, the model will be designed to run every
month or every 6 months to take account of any inci-
dences in relation to self-harm. Parameter uncertainty will
be addressed through probabilistic sensitivity analysis
using Monte Carlo simulation.
The outputs of both the within-trial analysis and the
decision analysis model will be presented as the expected
incremental cost-effectiveness ratios of FT compared to
TAU, scatter plots on the cost-effectiveness plane and
cost-effectiveness acceptability curves. The expected net
benefit of FT compared to TAU will be presented assum-
ing a threshold value of £20 k to £30 k per QALY. Further
sensitivity analyses for both analyses will consider add-
itional QALY gains to the caregiver using their answers to
the HUI3 questionnaire and additional costs from societal
perspective including out-of-pocket expenses, productivity
costs to the patients and carers and use of education and
justice services.
Discussion
The project was funded by the NIHR Health Technology
Assessment (HTA) Programme in response to a commis-
sioned call. The HTA had identified a gap in the evidence
relating to the most appropriate treatment to recommend
following self-harm in adolescents. The HTA were very
specific that a randomised controlled trial of family therapy
versus conventional care was needed for young people,
aged 11 to 17, who had self-harmed on more than one
occasion.
Design issues
During the design phase several methodological com-
plexities were encountered, each requiring careful con-
sideration. The delivery of behavioural/psychological
interventions, as in SHIFT, involves a number of differ-
ent therapists with varying experience, hence our first
challenge was to choose an appropriate method of ran-
domisation and determine strategies for minimising
therapist variation in the FT arm. Using standardised
training and supervision processes, we can measure and
describe the effect of therapists on outcomes and ensure
that the validity of the trial is optimised. As dropout
from treatment and follow-up is common following
self-harm in clinical services, and also in trials of this
nature, the choice of primary outcome is key. Our sec-
ond challenge was therefore to choose an endpoint that
would minimise the loss-to-follow-up rate and be an ob-
jective and quantifiable outcome; using hospital attend-
ance data, especially from a central routine data source
(HSCIC), maximises accurate and reliable data collection,
with secondary outcomes collecting self-reported self-
harm to account for self-harm that does not result in
hospital attendance. Safety reporting is well established for
trials of pharmacological interventions, but this is not the
case for trials of behavioural or psychological interven-
tions. Consequently, to ensure adequate safety reporting,
we needed to define clearly the expected serious and non-
serious adverse events, taking into account the character-
istics of the population under investigation. An independ-
ent data monitoring and ethics committee was convened
to review the safety of the trial during recruitment and
follow-up, and a formal interim analysis of the primary
endpoint was undertaken to review the safety of family
therapy. Finally, a further complexity during the design of
SHIFT was the consideration of appropriate analysis tech-
niques. As trial designs become more complicated, so does
the analysis, especially when different therapists are in-
volved in delivering the interventions, or when multiple
events can be observed such as in SHIFT. Cox’s Propor-
tional Hazards model will be used to test for differences in
repetition rates whilst secondary analyses will examine the
robustness of the conclusions from the primary analysis.
Multiple events analysis will make use of the timing and
number of first and subsequent self-harm events, and
multilevel survival frailty models will determine the extent
of clustering on outcome due to therapists and the impact
on the precision of the treatment effect.
Clinical service engagement
During the early stages of implementation of the trial
CAMH Services were slow to engage with SHIFT. We
deemed the slow initial recruitment a consequence of clin-
ical unfamiliarity with research in many sites, the pressures
of routine clinical practice and the sheer size of the task of
involving so many clinicians in trial processes. The nature
of the trial was such that anyone within the clinical team
undertaking referral assessments could consider a young
person’s eligibility for the trial and then be involved in
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TAU delivery. Ensuring all clinicians were fully informed
about trial processes and had the research materials avail-
able was logistically complex. Very regular contact between
the trial team and local services facilitated a collaborative
and flexible approach, and was helped by the appointment
of local trial ‘champions’ who took a lead in reminding
their local colleagues of trial procedures. This process took
the form of newsletters circulated by CTRU, posters for
staff rooms and formal presentations delivered at research
or team events. In addition, a training DVD was produced
in which the Chief Investigator, researchers and trial thera-
pists discussed the salient points of the trial in a short ex-
planatory piece designed for clinicians.
Data collection from a large number of clinicians was
not straightforward as there was little opportunity for
learning on the clinicians’ part, a TAU clinician might only
see one or two SHIFT participants over the duration of the
trial so there is opportunity for missing data. Data collec-
tion (from clinicians) was thus a labour intensive task, and
was ultimately superseded by data collection by researchers
(where they could be un-blinded – for example, at the end
of follow-up) and by Clinical Research Networks’ Clinical
Studies Officers.
Despite the complexity of SHIFT, the trial ultimately re-
cruited well, following implementation of intensive mea-
sures to improve screening and recruitment in 2010 after
a slow start in 2009, and was able to complete recruitment
at the end of 2013 following an extension award by HTA.
The main results relating to the primary outcome will
inform treatment of those referred to CAMHS follow-
ing self-harm via a definitive recommendation regard-
ing the effectiveness of the SHIFT Family Therapy
approach. There is also the opportunity for much sub-
study work looking in more detail at the secondary
outcomes and investigation into the mediating and
moderating factors influencing therapeutic outcome, as
well as into the therapeutic process itself.
Trial status
The Data Monitoring and Ethics Committee met in July
2013 to review the safety of family therapy in a formal in-
terim analysis of the primary endpoint, at which point no
concerns were raised, and it was recommended that SHIFT
continue to recruit the full sample. SHIFT completed
recruitment following the randomisation of 832 young
people in December 2013. SHIFT is now nearing the end
of the 18-month follow-up period for all participants. The
HTA monograph will be submitted in April 2016.
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